Actinium
- Generic Name
- Actinium
- Drug Type
- Small Molecule
- Chemical Formula
- Ac
- CAS Number
- 7440-34-8
- Unique Ingredient Identifier
- NIK1K0956U
- Background
Actinium has been investigated for the treatment of Breast Cancer and Pulmonary Disease, Chronic Obstructive.
Lutetium-PSMA Combination Therapies Show Promise in Advanced Prostate Cancer
• Combining Lutetium-PSMA with hormonal therapies like enzalutamide demonstrates improved PSA progression-free survival in metastatic castration-resistant prostate cancer (mCRPC).
• The ENZA-p trial showed a high PSA response rate (80%) with the combination of enzalutamide and lutetium-PSMA-617, suggesting enhanced efficacy in first-line mCRPC treatment.
• Research is exploring various combinations, including PARP inhibitors, taxanes, and immunotherapy, to overcome resistance and improve outcomes in prostate cancer theranostics.
• Adaptive dosing strategies and sequencing of therapies are being investigated to optimize treatment based on disease stage, patient needs, and the evolving understanding of tumor biology.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath